Cronos Group Inc. (CRON) Earnings Call Transcript & Summary
May 11, 2026
Earnings Call Speaker Segments
Operator
operatorGood morning, everyone. I'm Michelle, and I'll be serving as your conference operator for today. I'd like to welcome all of you to the Cronos conference call for the first quarter of 2026. This call is being recorded as of now. At this point, I'll hand things over to Harrison Aaron, our Senior Director of Investor Relations and Corporate Development. Sir, the floor is yours.
Harrison Aaron
executiveThanks, Michelle, and I appreciate everyone being here today as we go through Cronos' financial and business results for Q1 of 2026. With me on the call are Mike Gorenstein, our Chairman, President, and CEO, along with Anna Shlimak, our CFO. This morning Cronos put out a news release with our financial results, and it's been filed on our EDGAR and SEDAR+ profiles. That information, together with the prepared remarks, will also be available on our website in the Investor Relations section. Before handing things over to Mike, I want to remind everyone that during this call we may make forward-looking statements and refer to non-GAAP financial measures. Such forward-looking statements rest on management's current expectations and assumptions, and they carry risks and uncertainties that might lead actual results to differ materially from what those forward-looking statements project. The factors that might lead actual results to differ materially from expectations are laid out in our earnings materials and in our SEC filings, which you can access on our website, and by which any forward-looking statements made on this call are qualified in their entirety. Details on non-GAAP financial measures, including reconciliations to U.S. GAAP, are likewise available in the earnings materials posted on our website. Finally, throughout this conference call we will be making statements about market share information, and unless otherwise stated, all market share data comes from HiFi.
Harrison Aaron
executiveWe'll give our prepared remarks at this point, and after that we'll open things up for a question-and-answer session. So with that, I'll hand things over to Mike Gorenstein, who serves as Chairman, President, and CEO of Cronos.
Mike Gorenstein
executiveThanks, Harrison. In Q1 2026, Cronos posted record net revenue and gross profit as we kept executing against our strategic vision. Record net revenue came from international markets, and our Canadian brands gained share in key categories, with Spinach taking the number one market share position in vapes. Turning to Cronos Israel, Q1 marked our ninth consecutive quarter of record net revenue, up 53% year-over-year. We grew our market share lead, powered by PEACE NATURALS as the number one brand in Israel according to pharmacy data collected by Cronos. Quality genetics and our team's execution on the ground drove this performance. We were also very pleased with how the Lord Jones brand performed initially in Israel. We launched the brand with a lineup of curated premium flower offerings featuring cold-cured large flower buds in a series of limited-time drops. Initial reception has been strong, showing that the Lord Jones brand's premium positioning translates across markets. We look forward to building on this early momentum. With PEACE NATURALS, Lit, and Lord Jones, we now give Israeli pharmacies a comprehensive tiered product portfolio that addresses a spectrum of patient price points and broadens our market reach.
Mike Gorenstein
executiveNow looking at Canada: our brands posted retail sales growth of 18% versus the prior year, while the industry as a whole grew 2%, based on HiFi data. It was a standout quarter for the Spinach brand, and our product lineup showed how well our innovation work is paying off through sizable share gains. Spinach took the top spot across every vape format in Q1, with 9.8% of the total market. Within vape cartridges, Spinach's share came in at 11.1%, again ranking first. On top of that, the three top-selling vape SKUs nationwide in the quarter were all Spinach cartridges. That's a significant milestone, and it speaks to our continued investment in product quality and innovation as well as our reliance on consumer insights to shape the product development pipeline. Along those lines, Spinach Puffers kept expanding distribution and shaking up the market in Q1, widening its footprint across Canadian provinces following its initial launch in select markets late last year. Puffers climbed to the number two market share spot in the all-in-one vape category in March 2026, only four months after launch. Puffers is a great example of what we mean by raising the bar on product excellence, design, and flavor, and early consumer response has confirmed our confidence in the Puffers platform. In edibles, we held onto the number one position with 20.8% market share, and gummies stood at 22.7%.
Mike Gorenstein
executiveSOURZ by Spinach continues to be the undisputed leader in the edibles category, and the Fully Blasted multipack is driving that momentum. Since its launch in mid-2025, Fully Blasted products have earned four spots among the top 10 edible SKUs in Canada, including the number one SKU across the country in Q1. On the flower side, we moved up quarter-over-quarter from number four to number three in the rankings, which directly reflects how our supply constraints have eased now that the GrowCo expansion is complete. Last quarter we told you supply constraints should ease in 2026, and that is now beginning to materialize. In pre-rolls, we brought out Spinach STIX, the brand's first cylindrical-style pre-roll, in response to strong consumer demand for this fast-growing format. We introduced three STIX SKUs — GMO Cookies, Sour Chem, and Space Cake — along with new two-by-one-gram pre-rolls in Sour Chem and GMO Cookies. Those launches together lifted Spinach to the number eight market share position in non-infused pre-rolls in Q1. Moving to our other international markets, we achieved 97% year-over-year growth and posted record net revenue for the quarter, fueled by sustained momentum in Germany. Our PEACE NATURALS and Lit brands continue to power our international results, and the breadth of our footprint across markets offers significant additional growth potential and optionality as regulatory environments evolve.
Mike Gorenstein
executiveExpanding on the global progress we've been making, we’re still highly enthusiastic about the deal we have pending to acquire Canndoc. The definitive agreement was announced in December, and we are ready to complete it as long as certain closing conditions are met, with the transaction anticipated to wrap up in summer of 2026. To recap, Canndoc ranks as the biggest company active in the Netherlands' legal adult-use cannabis program and stands alone as an industrial-scale greenhouse cultivator. The Netherlands carries a rich cannabis tradition, and in our view this market could potentially act as a template for other European markets. Buying a market leader in Europe's biggest adult-use cannabis market represents a significant move in our international strategy and a chance to apply our borderless product strategy at scale. We’re eager to welcome Canndoc into the Cronos family and to build on the foundation and just establish. Cronos holds the strongest balance sheet in the industry, carrying no debt and $822 million in cash and cash equivalents, which lets us keep investing in growth, innovation, and global expansion. Today, we announced that our board has authorized a renewed $50 million share repurchase program. That choice mirrors our confidence in the long-term value of our business and our dedication to delivering returns to shareholders as we carry out our strategy.
Mike Gorenstein
executiveWith the strength of our balance sheet and profitability, there's an opportunity for us to put capital to work in organic growth, share repurchases, and M&A. At this point, I'll hand things over to Anna, who will take you through the financials for our first quarter.
Anna Shlimak
executiveThanks, Mike, and good morning to everyone. I'll take you through the results for the first quarter of 2026 now. Consolidated net revenue came in at $45.2 million for the company, which is a 40% rise compared with the same period a year earlier. That increase in net revenue came from greater sales of cannabis flower in Israel, Canada, and other countries, along with stronger cannabis extract sales within the Canadian market. Gross profit and adjusted gross profit for the first quarter stood at $19.2 million, which works out to 39% growth over the adjusted gross profit of Q1 2025. The gain versus last year was mostly the result of higher sales volumes and higher average sales prices, largely because of a mix shift toward Israel and other countries, where no excise tax applies. Operating expenses, excluding restructuring costs and impairments, totaled $20.5 million in the quarter, up $3.3 million from a year earlier, driven by increases in G&A, sales and marketing, and R&D expenses. Keep in mind that $1.3 million of the G&A increase within opex comes from discrete costs mainly tied to transaction costs incurred in connection with the Canndoc acquisition. Adjusted EBITDA for the first quarter was $5.1 million, an improvement of $2.8 million versus last year, driven by higher gross profit and partly offset by higher operating expenses. Moving to the balance sheet and cash flow statement, the company finished the quarter with $822 million in cash, cash equivalents, and short-term investments, which is down $10 million from Q4 2025, driven by $17 million of share repurchases, $2 million of capex spend, and $2 million of withholding taxes paid on share-based compensation, partly offset by positive cash flow from operations before changes in working capital of $11 million.
Anna Shlimak
executiveBeyond that cash position, we also have loans receivable totaling $21 million, along with $5 million in other investments. To sum up, Q1 saw us achieve record net revenue and record gross profit, with robust gross margins and adjusted EBITDA ranking as the second-highest ever recorded by the company. This reflects the fundamental strength of our business and the team's ongoing dedication to execution. With that said, I'll turn things back over to Mike for a quick remark ahead of Q&A.
Mike Gorenstein
executiveThanks, Anna. Q1 got 2026 off to a strong start, with record net revenue and record gross profit. In Canada, Spinach hit number one in vapes for the first time, while holding or improving its market-leading spot in every category we compete in. Cronos Israel turned in another record quarter, and our international markets outside Israel almost doubled year-over-year. We're building something differentiated: a branded portfolio of innovative products that connect with consumers in any market, backed by an expanding and efficient production platform and the strongest balance sheet in the industry. The GrowCo expansion is now online. We expect to close the Canndoc acquisition this summer, adding Europe's largest adult-use cannabis business to our footprint, and we head into the rest of 2026 with momentum, financial flexibility, and a team that knows how to execute. Thank you — we'll now open the line for questions.
Operator
operatorThank you. If you'd like to pose a question, press star 1 1 on your phone and hold until your name is called. Should you need to cancel your question, just press star 1 1 once more. We'd ask that everyone stick to one question plus one follow-up before getting back in line. Please hold a moment while we take the first question. That first question comes from Kenric Tyghe at Canaccord Genuity Capital Markets. Your line is open. Go ahead, please.
Kenric Tyghe
analystThanks. Morning, and congratulations on the quarter. Mike, a quick question for you about the GrowCo expansion and that ramp — specifically regarding your targets for efficiency and throughput, where would you say you stand in that journey right now, and how does that compare with what you expected?
Mike Gorenstein
executiveThanks. That's a really good question. From last quarter to this one, we've definitely seen a jump in efficiency and progress. You've seen a good chunk of us getting things online and working through the ramp-up. There are still some efficiencies we'll dial in over the quarters ahead. As far as being planted and having the throughput, we're there now.
Kenric Tyghe
analystThanks for that. So I’ll pivot quickly: regarding the Canndoc long-stop date extension, is that simply extra caution by pushing it through September so this doesn’t turn into a back-and-forth process? Or do you believe, on balance of probabilities, there’s a chance it closes only in the third quarter rather than late in the second?
Mike Gorenstein
executiveMy view is that this is erring well on the side of caution. Nothing has come up that would create any problems. It is definitely taking a while, I'll grant that, but several licensed producers taking part in the experiment have already received approval, and at this point it's simply a matter of waiting for Bibob to work through it. Our confidence in the process is solid, and we have not encountered any issues.
Kenric Tyghe
analystPerfect, thanks. I’ll rejoin the queue.
Operator
operatorThanks, and give us a moment while we bring up the next question. That next question is going to come from Bill Kirk at Roth Capital Partners. Your line is open — please go ahead.
Bill Kirk
analystMorning, everyone. Mike, I’d really like to hear your take on the rescheduling developments in the US, and perhaps how that changes the way you view that market, as well as Cronos’ intentions regarding participation—whether it will take part, stay out, or be involved in some way. Maybe we could begin there with your view on the rescheduling announcements that have come out so far.
Mike Gorenstein
executiveYeah, absolutely. I'd call this a really, really exciting announcement and development. I think it's one of the most significant milestones we've seen in the US regulatory environment over the last 10 years. As always, the devil's in the details, and there are still some things that need to be worked out, but we're quite optimistic, and I think that when you compare how this was announced and what the early indications look like versus maybe the last few iterations of rescheduling, this seems very positive. We're continuing to monitor and figure out what the best spot for us is. I would say that what I'm really focused on is what opportunities end up being created from an interstate perspective and then also an international perspective, and I think that how state laws end up changing and how some of those details work out will really dictate where we move in.
Bill Kirk
analystAlright. If I may, I'd like to ask one more about capacity expansion and GrowCo, and perhaps about how that product ends up being allocated. As for GrowCo's expansion, where does it stand in terms of maturity? What can it do at present compared with what you believe it will be capable of, say, 12 months from now?
Mike Gorenstein
executiveI believe we discussed this when we were projecting ahead that you get through a first harvest or 2 harvests, and that ramp-up represents a big step, and since we've moved beyond that point, we're now at the stage where, with each harvest after that, efficiency gets dialed in during the first year. You're looking at smaller percentage gains, and they wouldn't be massive changes. Of course, depending on what the season is, light can affect yields. I think we can now shift back to how do we dial in efficiencies and increase yields versus how do we get everything planted, get everything harvested. You can expect some efficiency gains and some extra yields, but it's not going to be, I think, a dramatic step change.
Bill Kirk
analystAppreciate that. I'll make sure it gets to the right people.
Operator
operatorThanks, and give us just a second while we bring up the next question. That next question is from Derek Lessard at TD Cowen. Your line is open — please go ahead.
Derek Lessard
analystMorning, Mike and Anna. Congratulations on such a solid quarter. I suppose I mainly wanted to ask about your number one market share position. Maybe just walk us through, Mike, the particular levers driving those share gains, and how do you see your playbook shaping up going forward?
Mike Gorenstein
executiveThanks, Derek. I’m assuming you mean Canada — I’m not certain which market you have in mind.
Derek Lessard
analystHowever—Mike, that's Canada. My apologies.
Mike Gorenstein
executiveSure. So, one major factor influencing our share is clearly in flower and the availability we have. We're constantly going back and forth on whether we've got sufficient capacity to allocate across all the markets, and how we distribute it among those markets. This quarter, I think you saw that due to the capacity increase, we had more flower available for Canada, and that let us satisfy a lot of unconstrained demand. I still believe you'll see additional unconstrained demand, and then as things also grow in Israel and Europe, that's just something we'll need to examine quarter-to-quarter — how we allocate and really optimize overall for margin. I think another big change was what we managed to accomplish with vapes. The largest innovation, the biggest shift, came down to Puffers. It's something we've been working on for quite a while, and we hadn't really been a meaningful participant in all-in-one vapes, which is a really large category. You're seeing that momentum, and I think you're going to see that momentum carry on throughout the year. And now we believe the big lever for us to pull is going to be in pre-rolls, where we still have some work to do.
Derek Lessard
analystGreat. With that success in mind, I was wondering whether you could say a bit about how intense the competition is, again in Canada and in those categories, and what you're doing—given your strength—perhaps to safeguard your margins.
Mike Gorenstein
executiveMy take is that competitive conditions have actually been harder for us before than what we're facing today, largely because a lot of the pull goes to Europe, and of course it varies by category, but I think that as we keep scaling, our fixed-cost absorption improves, we can bring costs down, and that gives us the flexibility to compete as needed, though we don't feel like we're in the same kind of deflationary environment that existed in the past.
Derek Lessard
analystAppreciate it, Mike.
Operator
operatorThanks, and please hold for the next question. Our following question comes from Pablo Zuanic at Zuanic & Associates. Your line is open — go ahead.
Pablo Zuanic
analystThanks, and morning to all of you. Mike, would you mind weighing in on the Netherlands — specifically what's happening in the pilot towns when it comes to market conditions, whether that's market size, growth trends, competitive dynamics, or pricing? And staying on that same subject, the summer review is expected to wrap up shortly — do you anticipate anything coming out of it, such as additional licenses granted to more licensed producers, or additional towns being added to the pilot? Thanks.
Mike Gorenstein
executiveSure, thank you. I think you've watched the competition pick up somewhat, because one of the licensed producers that hadn't been online is now online, and you've seen certain companies tighten up their efficiencies, yet at the same time the market is expanding a little, so in terms of competitive dynamics, it isn't truly as fierce as what you've witnessed in Canada or Israel. I think there's still some distance to travel when it comes to innovation of that kind in the market, and that is something that arrives along with maturity. You might see some store changes in one of the municipalities, where a handful will go offline, but a few additional stores are going to open; in Groningen, a few will close and then reopen, but on a net basis, we ought to be adding stores, and that will unfold across the coming year or so. I'm not sure whether it's something you'll see make a big enough impact on the market in either direction, but there will be some movement in stores there. After that, I don't anticipate changes stemming from the summer review. I think that is really more a matter of demonstrating the data on how the program is progressing.
Mike Gorenstein
executiveIn my view, the program has performed quite strongly, and that is precisely the sort of thing that will help drive matters ahead going forward.
Pablo Zuanic
analystThanks. I’ll ask just one brief follow-up here. I realize this may really be a question directed more at Altria, but given the CEO transition—Sal stepping in for Billy—could there be potential implications for Cronos, or perhaps you could describe how you’ve dealt with both the former CEO and the incoming one? Any detail you’re able to offer would be useful, particularly since BAT has been so active in this area through its affiliates when it comes to M&A. Thanks.
Mike Gorenstein
executiveMy view is that our relationship with Sal is strong. We’ve been aware that Altria has a lot of continuity, we’ve been familiar with the management teams, and we don’t perceive any shift. I think that when you examine the activity, one reason it appears Altria is less active is simply that we haven’t required extra capital, so that translates into somewhat fewer actions from them, but they remain involved via the board. We continue to be in ongoing dialogue, and I believe everyone is very happy with the progress and with what’s happening.
Pablo Zuanic
analystThanks. If I could, I realize the limit is two questions, but may I add a third? Regarding how you align your overseas approach across GrowCo and Cronos, does that work as a single combined company operating abroad, or is there a degree of rivalry between them? Could you shed some light on that? Thank you.
Mike Gorenstein
executiveWe are quite tightly aligned. Given how the board works and simply how we operate together day to day, there is very close coordination between us. We carry the identical Cronos name, the identical genetics, the identical products, and the identical governance — so I would describe it as a very, very tight relationship, and one that is nearer to being a single company than two distinct ones.
Pablo Zuanic
analystI appreciate that.
Operator
operatorThanks, and please hold for the next question. We have a follow-up coming in from Derek Lessard at TD Cowen. Your line is open — go ahead whenever you're ready.
Derek Lessard
analystMike, I have just one more question. The PEACE NATURALS brand is evidently still striking a chord with buyers. Could you perhaps discuss what is happening in the Israeli market and a few of the openings you are spotting there?
Mike Gorenstein
executiveI mean, Israel has been a somewhat distinctive market for us for a year, well, actually more than a year now. I really believe consistency matters a great deal. Patients in that market genuinely expect the same quality of product to be on the shelf, and we've done quite well at maintaining that. Sure, there are new strains we can bring in, though we do it in a careful way and make certain we stay consistent with them. In a medical market, that's truly a crucial distinction — guaranteeing that availability holds up. We've examined other formats as well, but honestly genetics are what I see as driving most of the differentiation. Beyond PEACE NATURALS, Lord Jones also represented a genuinely incremental opportunity for us. Having premium alongside, say, a value and mainstream offering means we can present more options when we visit the various pharmacies, and it simply reinforces our distribution footprint.
Derek Lessard
analystThat's great. Thank you, Mike, and congratulations once more.
Operator
operatorThank you. That brings today's Q&A portion to a close, ladies and gentlemen. With that, we're also wrapping up the conference call for today. We appreciate your participation, and you're welcome to disconnect at this point. Have a wonderful day, everyone.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.